Patrys has assembled an international panel of critical care specialists to steer the development of RLS-2202, its injectable formulation of quetiapine for delirium in acute-care settings.

Tetratherix has reported early animal results for a cataract surgery gel that it says can be left in the eye without triggering the pressure spike, the most common early complication of the procedure.

AusBiotech has welcomed concessions to changes to the R&D Tax Incentive and Capital Gains Tax but remains concerned about the potential impact on emerging life sciences companies.

Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the most common form of brain cancer.

Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug. Three months later, all of them were still doing better. Half of them had not binged once.

Noxopharm announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful, disfiguring skin condition with no targeted treatment currently available.

The controlled release covers Promarker D, a test that assesses a patient's risk of developing diabetic kidney disease up to four years before symptoms appear, and Promarker Eso, which helps rule out oesophageal cancer in patients suffering from chronic reflux.

The Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.

The grant, announced by Neurizon, will finance an Expanded Access Protocol for NUZ-001, the company's lead drug candidate for amyotrophic lateral sclerosis, commonly known as ALS or motor neurone disease.

Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest-to-treat forms of cancer.

CLINUVEL, a Melbourne- and Singapore-based biopharmaceutical company, has completed development of a proprietary single-use device designed to administer controlled-release drug formulations under the skin.

A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now treated its 100th patient in Spain.

Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new chief executive officer.

Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB.

Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of ALA-101 and opened its first trial site at The Alfred Hospital in Melbourne.

OncoSil Medical has secured $5.6 million in fresh capital from its three biggest institutional shareholders, giving the Sydney-based medical device company the financial firepower to launch its targeted radiation therapy in the United States and Australia after years of regulatory work.

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.